Efforts to Develop Pfs25 Vaccines

View More View Less
  • 1 PATH Essential Medicines, PATH, Seattle, Washington

Acknowledging the fallibilities of recalling events from more than three decades ago, the recollection of Richard Carter’s impact on the identification and development of Pfs25, a major surface protein of Plasmodium falciparum zygotes and ookinetes, and target of malaria transmission-blocking vaccines, remains unassailable. In fondest memories of Richard Carter’s many contributions, herein retells some memorable events along the tortuous journey toward the development of Pfs25 vaccines.

Author Notes

Address correspondence to David C. Kaslow, PATH, 2201 Westlake Ave., Ste. 200, Seattle, WA 98121. E-mail: dkaslow@path.org

Financial support: Preparation of this manuscript was supported, in part, by the Bill & Melinda Gates Foundation (OPP1180199).

Disclaimer: The funder had no role in the preparation of the manuscript or the decision to publish.

Disclosure: D. C. K. is an inventor on Pfs25 and other malaria vaccine patents but receives no financial compensation from any patents. He is an employee of PATH (a not-for-profit, international nongovernmental organization) and has no financial interest in any for-profit entity.

Author’s address: David C. Kaslow, PATH Essential Medicines, PATH, Seattle, WA, E-mail: dkaslow@path.org.